NASDAQ · UPC
Universe Pharmaceuticals financials
$4.52−5.83%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q4 '25 Sep 30 | Q4 '24 Sep 30 | Q4 '23 Sep 30 | Q4 '22 Sep 30 | Q4 '21 Sep 30 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Gross margin | — | — | — | — | — |
| Operating income | — | — | — | — | — |
| Net income | — | — | — | — | — |
| Net margin | — | — | — | — | — |
| Diluted EPS | — | — | — | — | — |
| EBITDA | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating cash flow | — | — | — | — | — |
| Free cash flow | — | — | — | — | — |
| Diluted shares | 455.9M | 13.9M | 6.0M | 0.0M | 0.0M |
Balance sheet
| Period end | Sep 30 | Sep 30 | Sep 30 | Mar 31 | Sep 30 | Sep 30 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $33.59B | $29.50B | $5.3M | $13.0M | $5.7M | $8.1M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $13.3M | $13.1M | $13.7M |
| Total debt | $9.26B | $7.99B | $5.5M | $4.1M | $3.9M | $4.3M |
| Total assets | $69.30B | $67.95B | $41.7M | $70.4M | $59.5M | $70.1M |
| Total liabilities | $13.17B | $22.45B | $13.8M | $23.2M | $13.1M | $11.2M |
| Shareholders' equity | $56.13B | $45.50B | $28.0M | $47.1M | $46.4M | $58.9M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology